Zhejiang Orient Gene Biotech Co Ltd (688298) — Capital Reinvestment Ratio

Latest as of September 2022: 0.39x

Zhejiang Orient Gene Biotech Co Ltd (688298) has a Capital Reinvestment Ratio of 0.39x as of September 2022, meaning it reinvests 0% of its operating cash flow (CN¥309.89 Million) in capital expenditures (CN¥119.58 Million). Check 688298 tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.39x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥309.89 Million
CNY

Capital Expenditures

CN¥119.58 Million
CNY

Data as of

Sep 2022
Most recent filing

Zhejiang Orient Gene Biotech Co Ltd Capital Reinvestment Ratio (2016–2022)

This chart tracks Zhejiang Orient Gene Biotech Co Ltd's Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see 688298 operating cash flow.

Annual Capital Reinvestment Ratio for Zhejiang Orient Gene Biotech Co Ltd (2016–2022)

Year-by-year Capital Reinvestment Ratio for Zhejiang Orient Gene Biotech Co Ltd from 2016 to 2022. See cash generation quality of Zhejiang Orient Gene Biotech Co Ltd to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2022 0.35x CN¥3.00 Billion CN¥1.05 Billion ▲ +259.8%
2021 0.10x CN¥5.20 Billion CN¥507.87 Million ▲ +37.7%
2020 0.07x CN¥1.79 Billion CN¥126.93 Million ▼ -67.7%
2019 0.22x CN¥54.21 Million CN¥11.90 Million ▼ -48.5%
2018 0.43x CN¥44.33 Million CN¥18.88 Million ▲ +6.7%
2017 0.40x CN¥33.54 Million CN¥13.38 Million ▲ +1.3%
2016 0.39x CN¥11.81 Million CN¥4.65 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow